ArticleAntibiotics (Basel, Switzerland)2021
Investigating the OXA Variants of ESKAPE Pathogens.
Article in Antibiotics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- A monoclonal antibody targeting OXA23 restores carbapenem susceptibility in global epidemic carbapenem-resistantAntimicrobial agents and chemotherapy · 2026Article
- A Cautionary Case for Host Assignment Based on Broad Environmental blaEnvironmental microbiology reports · 2026Article
- Genetic and virulence analysis of carbapenem-resistant Pseudomonas aeruginosa in farm animals in Shandong province, China: implications for human health.BMC microbiology · 2025Article
- AmpC β-lactamases: A key to antibiotic resistance in ESKAPE pathogens.Cell surface (Amsterdam, Netherlands) · 2025Article
- Subinhibitory Concentrations of Oxacillin Alter Motility, Biofilm Production, and Transformation Capability of the Oxacillinase-Producing Acinetobacter baumannii.Current microbiology · 2025Article
- Genomic and phenotypic characterization of six multidrug-resistant Acinetobacter pittii isolates.Scientific reports · 2025Article
- Genomic epidemiology and characterization of difficult-to-treat resistant Pseudomonas aeruginosa isolates co-harboring blaScientific reports · 2025Article
- Riverine antibiotic resistome along an anthropogenic gradient.Frontiers in microbiology · 2025Article
- A review on the mechanistic details of OXA enzymes of ESKAPE pathogens.Pathogens and global health · 2023Review
- Article
- Efficacy andFrontiers in cellular and infection microbiology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
ESKAPE pathogens are the leading cause of nosocomial infections. The Global Priority List of WHO has categorized ESKAPE as priority 1 and 2 pathogens. Even though several mechanisms contribute to antimicrobial resistance, OXA β-lactamase has emerged as a new threat in combating nosocomial infections. In the present study we have investigated the presence of OXA and their variants, copy number, distribution on chromosomes/plasmids, subfamilies, phylogenetic relationships, amino acid identities and variabilities in ESKAPE pathogens. Our results revealed that a total of 929 OXA were present in 2258 completely assembled genomes, which could be further subdivided into 16 sub-families. Among all the ESKAPE pathogens, OXA were highly prevalent in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.